ArticleNPJ precision oncology2026
Deep learning for predicting pituitary neuroendocrine tumour lineage and high-risk subtypes from histology.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Pituitary neuroendocrine tumours (PitNETs) exhibit significant heterogeneity, posing challenges for clinical management. We developed a deep learning model to predict PitNET lineage, high-risk subtypes, and recurrence directly from routine H&E-stained whole-slide images. Trained on 925 patients from USTC and externally validated on cohorts from Taihe Hospital (n = 226) and Huashan Hospital (n = 193), the model achieved a micro-average AUC of 0.912 for lineage classification (SF1: 0.926, PIT1: 0.932, TPIT: 0.904; Without distinct lineage: 0.706). High-risk subtype prediction yielded AUCs of 0.805 (PIT1), 0.753 (TPIT), and 0.733 (null cell). Recurrence prediction reached an AUC of 0.641. Analysis of the tumour microenvironment revealed that compared with primary tumours, recurrence tumours were characterized by an increased density of M2 macrophages and decreased infiltration of CD8 + T cells. Spatial transcriptomics further elucidated distinct molecular pathways associated with recurrence, providing mechanistic insights into prognostic predictions. Our deep learning model accurately predicts PitNET characteristics from routine H&E slides, and spatial biology validation identified distinct immune and molecular features associated with recurrence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.